IRIS PubliCatt

Miele, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.431
NA - Nord America 5.460
AS - Asia 1.133
AF - Africa 31
OC - Oceania 28
SA - Sud America 28
Continente sconosciuto - Info sul continente non disponibili 20
Totale 13.131
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.434
DE - Germania 2.316
SE - Svezia 1.451
IT - Italia 743
CN - Cina 719
IE - Irlanda 532
UA - Ucraina 478
FR - Francia 210
GB - Regno Unito 189
FI - Finlandia 183
TR - Turchia 133
IN - India 125
BE - Belgio 80
PL - Polonia 54
HK - Hong Kong 50
CH - Svizzera 49
IR - Iran 39
CZ - Repubblica Ceca 32
RU - Federazione Russa 31
AU - Australia 24
JP - Giappone 23
CI - Costa d'Avorio 20
EU - Europa 17
NL - Olanda 17
BR - Brasile 16
SG - Singapore 14
RO - Romania 13
CA - Canada 10
PT - Portogallo 10
AT - Austria 9
ES - Italia 9
CL - Cile 6
MX - Messico 6
BZ - Belize 5
DK - Danimarca 5
HU - Ungheria 5
IL - Israele 5
KR - Corea 4
NG - Nigeria 4
NZ - Nuova Zelanda 4
CO - Colombia 3
GR - Grecia 3
MY - Malesia 3
PA - Panama 3
PH - Filippine 3
VN - Vietnam 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
EE - Estonia 2
HR - Croazia 2
ID - Indonesia 2
IQ - Iraq 2
NO - Norvegia 2
PK - Pakistan 2
PR - Porto Rico 2
RE - Reunion 2
SC - Seychelles 2
A1 - Anonimo 1
AR - Argentina 1
BO - Bolivia 1
BY - Bielorussia 1
DJ - Gibuti 1
EG - Egitto 1
MA - Marocco 1
MC - Monaco 1
MD - Moldavia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
PY - Paraguay 1
RS - Serbia 1
SA - Arabia Saudita 1
SI - Slovenia 1
TH - Thailandia 1
TW - Taiwan 1
Totale 13.131
Salva come PNG Salva come JPEG
Città #
Chandler 1.055
Dublin 532
Ashburn 455
Chicago 299
Jacksonville 279
San Mateo 247
New York 189
Nanjing 188
Nürnberg 154
Milan 148
Wilmington 145
Ann Arbor 142
Boston 137
Rome 124
Izmir 123
Houston 121
Marseille 112
Princeton 112
Dearborn 106
Cattolica 100
Munich 90
Beijing 89
Helsinki 85
Woodbridge 84
Brussels 79
Nanchang 77
Seattle 71
Redmond 53
Kraków 50
Fairfield 49
Hong Kong 46
Hebei 45
Redwood City 44
Zurich 40
Shenyang 39
Tianjin 39
Boardman 37
Bremen 36
Lawrence 35
Kunming 31
Norwalk 30
Zhengzhou 30
Brno 29
Changsha 26
Mountain View 26
San Jose 26
Fremont 24
Guangzhou 22
Jiaxing 21
Pune 21
University Park 21
Abidjan 20
Hangzhou 20
Andover 17
Augusta 17
Castelnuovo di Val di Cecina 17
Washington 17
Cambridge 16
Kish 16
Leawood 16
Portland 16
Trieste 16
Jinan 15
London 15
San Diego 15
Falls Church 13
Lancaster 13
Los Angeles 13
Lanzhou 12
Ningbo 12
Boydton 11
Busto Arsizio 10
Simi Valley 10
Stockholm 10
Taizhou 10
Tokyo 10
Hefei 9
Palermo 9
Rio de Janeiro 9
Atlanta 8
Campagna 8
Shanghai 8
Amsterdam 7
Bern 7
Gunzenhausen 7
Provo 7
Singapore 7
Buffalo 6
Chiswick 6
Detroit 6
Falkenstein 6
Hounslow 6
Lappeenranta 6
Phoenix 6
Belize City 5
Costa Mesa 5
Edinburgh 5
Frankfurt am Main 5
Indiana 5
Tabriz 5
Totale 6.678
Salva come PNG Salva come JPEG
Nome #
Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging 378
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 202
A phase II study of sunitinib in advanced hepatocellular carcinoma 200
13C-methionine breath tests for mitochondrial liver function assessment. 198
13C-breath tests in the study of microsomal liver function 189
gc) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. 177
-Hepatic steatosis and vascular disease 164
Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms 156
Role of diffusion-weighted imaging, apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver 149
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis 148
134C-breath tests in the study of mitochondrial liver function 144
Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. 143
Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms 140
Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels 133
13C-breath tests in the study of microsomial liver function 132
Effect of sildenafil on diabetic gastropathy. 129
Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm 125
Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels 122
13C-methionine breath tests for mitochondrial liver function assessment 119
The Effect of CYP, GST, and SULT Polymorphisms and Their Interaction with Smoking on the Risk of Hepatocellular Carcinoma 114
gc) Celiac disease in the 21st century: issues of under- and over-diagnosis 113
[Oxidative stress in metabolic syndrome and nonalcoholic steatohepatitis. Is it possible a role for vitamins in clinical practice?] 112
[Helicobacter pylori infection: from gastric to systemic disease] 110
13C-breath tests in the study of mitochondrial liver function 108
Assessment of neurological manifestations in hospitalized patients with COVID-19 108
Potential use of liver function breath tests in the clinical practice. 107
Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival 106
[The treatment of hepatocellular carcinoma: an update] 101
Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels 97
Tromboembolism and breast cancer: the hidden risk for patient and physician 97
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 97
Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). 96
gastroesophageal reflux disease: facts and uncertaines 96
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome 96
-Fatty liver and drugs 95
Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. 95
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis 93
Intrafamilial transmission of hepatitis C virus in Italy: a systematic review 91
Cystic lymphangioma of the mesentery and hyposplenism in celiac disease. 91
A case-control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease 91
Cryoglobulinemia: a true internistic disease? 90
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome 90
An Attempt of Specific Desensitizing Treatment with Gliadin in Coleliac Disease 89
A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease 87
Liver transplantation in patients with alcoholic liver disease: A retrospective study 84
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 84
Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease 83
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome 81
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease 81
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. 80
Alcoholic and nonalcoholic forms of fatty liver disease. 78
Gallstone disease is associated with more severe liver damage in patients with non-alcoholic Fatty liver disease 78
-Nonalcoholic fatty liver disease: defining a common problem 78
High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study 78
Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets 78
Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial 77
Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target 77
Braised liver with herbs: the risks of naturopathic hepatoprotection. 76
A case of variant angina in a patient under chronic treatment with sorafenib 74
Socio-demographic determinants of coinfections by HIV, hepatitis B and hepatitis C viruses in central Italian prisoners. 72
Review article: breath testing for human liver function assessment. 72
A giant calcified hepatic mass 72
Is coeliac disease a confounding factor in the diagnosis of NASH? 71
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 71
Gender affects 13C-ketoisocaproic acid breath test 70
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 68
Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1) 68
Impairment of recent thymic emigrants in HCV infection. 67
A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease 67
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 67
Drug-induced hepatitis 66
Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH) 66
Impact of new DAA therapy on real clinical practice: A multicenter region-wide cohort study 66
The diagnostic performance of PIVKA-II in metabolic and viral hepatocellular carcinoma: A pilot study 65
Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind 64
Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma 63
"tear-drop shaped" HCC 62
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 62
Focus on fatty liver in clinical practice 61
NON ALCOHOLIC STEATOHEPATITIS (NASH) INDUCED BY CARBAMAZEPINE AND VARIEGATE PORPHYRIA 61
A case of esomeprazole-induced transient diabetes and hepatitis: the role of liver inflammation in the pathogenesis of insulin resistance 61
anticholinergic syndrome due to " Devil's herb': when risks come from the ancient time 61
Sporadic HEV hepatitis in Italy. 60
NAFLD and NASH: behind the fat, there's something more. 60
Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome 60
Propafenone-related cholestatic hepatitis in an elderly patient. 60
Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk 59
Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients 59
Mediterranean diet and the prevention of non-alcoholic fatty liver disease: Results from a case-control study 59
Biology, epidemiology, clinical aspects of hepatocellular carcinoma and the role of Sorafenib 58
Enhanced liver fibrosis test as a reliable tool for assessing fibrosis in nonalcoholic fatty liver disease in a clinical setting 57
-The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis. 56
Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk 56
IgG cryoglobulinemia 56
High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection 54
When was celiac disease born?: the Italian case from the archeologic site of Cosa 54
Acute HEV hepatitis: clinical and laboratory diagnosis 54
Liver transplantation in alcoholic patients: Impact of an alcohol addiction unit within a liver transplant center 54
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test 53
Liver transplantation for drug-induced acute liver failure 53
Totale 9.350
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.642
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.642
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019426 0 0 0 0 0 0 0 0 0 109 191 126
2019/20201.490 309 100 81 60 92 123 167 70 96 140 130 122
2020/20211.148 60 113 54 120 149 52 127 19 148 66 214 26
2021/20221.508 46 109 48 174 104 33 21 230 54 91 283 315
2022/20234.061 424 410 226 431 415 562 273 317 434 268 226 75
2023/20242.172 236 780 102 169 152 324 209 94 41 65 0 0
Totale 13.487